IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 241 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.32 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $15,995,888 | +500.1% | 1,994,500 | +1009.0% | 0.01% | +400.0% |
| Q1 2024 | $2,665,377 | +82.2% | 179,850 | -0.0% | 0.00% | 0.0% |
| Q4 2023 | $1,462,563 | +76.9% | 179,897 | -1.0% | 0.00% | – |
| Q3 2023 | $826,562 | +5.5% | 181,662 | +41.7% | 0.00% | – |
| Q2 2023 | $783,124 | 0.0% | 128,171 | 0.0% | 0.00% | – |
| Q1 2023 | $783,124 | -4.4% | 128,171 | 0.0% | 0.00% | – |
| Q4 2022 | $819,014 | -99.9% | 128,171 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $1,227,878,000 | -29.1% | 128,171 | -18.3% | 0.00% | 0.0% |
| Q2 2022 | $1,731,149,000 | -52.2% | 156,807 | -27.9% | 0.00% | -50.0% |
| Q1 2022 | $3,621,958,000 | +6.6% | 217,535 | +22.2% | 0.00% | +100.0% |
| Q4 2021 | $3,399,186,000 | -20.9% | 178,061 | +2.2% | 0.00% | -50.0% |
| Q3 2021 | $4,296,437,000 | -6.1% | 174,227 | -1.0% | 0.00% | 0.0% |
| Q2 2021 | $4,577,204,000 | -53.4% | 175,911 | -43.3% | 0.00% | -50.0% |
| Q1 2021 | $9,814,567,000 | -31.9% | 309,999 | -0.2% | 0.00% | -42.9% |
| Q4 2020 | $14,411,283,000 | +50.9% | 310,588 | +7.1% | 0.01% | +40.0% |
| Q3 2020 | $9,548,676,000 | +19.9% | 290,057 | -0.0% | 0.01% | 0.0% |
| Q2 2020 | $7,962,477,000 | +1.1% | 290,072 | +10.2% | 0.01% | -16.7% |
| Q1 2020 | $7,877,544,000 | +161.4% | 263,155 | +141.7% | 0.01% | +200.0% |
| Q4 2019 | $3,013,299,000 | +102.9% | 108,862 | +33.4% | 0.00% | +100.0% |
| Q3 2019 | $1,485,283,000 | -2.9% | 81,609 | +30.9% | 0.00% | 0.0% |
| Q2 2019 | $1,528,944,000 | +242.2% | 62,355 | +32.7% | 0.00% | – |
| Q1 2019 | $446,827,000 | +7.5% | 46,985 | 0.0% | 0.00% | – |
| Q4 2018 | $415,817,000 | +1.8% | 46,985 | +29.4% | 0.00% | – |
| Q3 2018 | $408,465,000 | -12.1% | 36,308 | 0.0% | 0.00% | – |
| Q2 2018 | $464,743,000 | -24.3% | 36,308 | 0.0% | 0.00% | – |
| Q1 2018 | $613,605,000 | +647.5% | 36,308 | +253.8% | 0.00% | – |
| Q4 2017 | $82,088,000 | +3.2% | 10,261 | 0.0% | 0.00% | – |
| Q3 2017 | $79,523,000 | +5.4% | 10,261 | 0.0% | 0.00% | – |
| Q2 2017 | $75,418,000 | – | 10,261 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MHR Fund Management | 19,997,103 | $90,986,819 | 11.15% |
| MPM BioImpact LLC | 3,287,397 | $14,957,656 | 3.99% |
| Perceptive Advisors | 11,962,938 | $54,431,367 | 1.82% |
| CM Management, LLC | 200,000 | $910,000 | 0.97% |
| Velan Capital Investment Management LP | 250,000 | $1,137,500 | 0.92% |
| Opaleye Management Inc. | 610,000 | $2,775,500 | 0.90% |
| Boxer Capital, LLC | 3,705,133 | $16,858,355 | 0.90% |
| SECTORAL ASSET MANAGEMENT INC | 985,000 | $4,481,750 | 0.87% |
| Parametrica Management Ltd | 95,400 | $434,070 | 0.73% |
| 683 Capital Management, LLC | 2,050,000 | $9,327,501 | 0.72% |